CTLA-4 bound for the clinic, Bristol-Myers hands CytomX $200M to kick off an expanded discovery pact
Over the last three years, Bristol-Myers Squibb has been steering four preclinical discovery programs it partnered on with South San Francisco-based CytomX, moving the lead CTLA-4 antibody to a near-term IND filing with an eye on first-in-human trials.
And now Bristol-Myers is signing up for eight more projects — six in oncology and two more outside of cancer, as CytomX pushes ahead in the clinic with a PD-L1 checkpoint the CEO believes can blitz its way through a pack of rivals and into the spotlight.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.